首页> 外国专利> METHODS OF TREATING PATIENTS HAVING MUTATIONS IN THE EXTRACELLULAR DOMAIN OF EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) WITH A COMBINATION OF THREE FULLY HUMAN MONOCLONAL ANTI-EGFR ANTIBODIES

METHODS OF TREATING PATIENTS HAVING MUTATIONS IN THE EXTRACELLULAR DOMAIN OF EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) WITH A COMBINATION OF THREE FULLY HUMAN MONOCLONAL ANTI-EGFR ANTIBODIES

机译:结合三种完整的人类单克隆抗EGFR抗体治疗表皮生长因子受体(EGFR)细胞外区域突变的患者的方法

摘要

Provided herein are methods of treating an epidermal growth factor receptor (EGFR) extracellular domain (ECD) mutant cancer in a human patient by administering to the patient an oligoclonal anti-epidermal growth factor receptor (anti-EGFR) antibody combination (e.g., MM-151, comprising a first monoclonal antibody (P1X), a second monoclonal antibody (P2X), and a third monoclonal antibody (P3X), wherein P1X, P2X and P3X are in a 2:2:1 molar ratio). In one embodiment, the cancer comprises at least one mutation in the extracellular domain of EGFR selected from the group consisting of EGFR R451C, S464L, K467T, G465R, G465E, I491M, and S492R.
机译:本文提供了通过向患者施用寡克隆抗表皮生长因子受体(抗EGFR)抗体组合(例如,MM- 151,包括第一单克隆抗体(P1X),第二单克隆抗体(P2X)和第三单克隆抗体(P3X),其中P1X,P2X和P3X的摩尔比为2:2:1。在一个实施方案中,所述癌症在选自EGFR R451C,S464L,K467T,G465R,G465E,I491M和S492R的EGFR的胞外域中包含至少一种突变。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号